NASDAQ$NUWE

Nuwellis Inc · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Nuwellis reported a net income due to warrant liability revaluation and achieved a gross margin increase and operating cost reduction.

Nuwellis, Inc. reported third quarter 2024 financial results with a revenue of $2.4 million. The company achieved a gross margin of 70% and reduced total operating costs by 30% compared to the prior-year quarter. Net income attributable to common shareholders was $2.4 million, primarily due to the revaluation of a prior period warrant liability.

  • Revenue was $2.4 million.
  • Pediatrics revenue grew by 28% compared to the prior year quarter.
  • Gross margin increased to 70% compared to 57.3% in the prior-year quarter.
  • Total operating costs decreased by 30% compared to the prior-year quarter.

Headline financials

Total Revenue

$2.37M

Previous: $2.41M-1.9%
EPS

$1.74

Previous: -$63.35+102.7%
Gross Margin

70.0%

Previous: 57.3%+22.2%
Weighted Avg Shares

204.7K

No prior period
Capital Expenditures

-$37K

Previous: -$185K+80.0%
Free Cash Flow

$2.32M

Previous: -$3.56M+165.3%
Net Income

$2.36M

Previous: -$3.37M+170.0%
Operating Income

-$1.53M

Previous: -$3.16M+51.6%
Gross Profit

$1.66M

Previous: $1.38M+19.9%
R&D Expense

$486K

Previous: $1.12M-56.5%
Stock-Based Comp

$101K

Previous: $135K-25.2%

Revenue & EPS history

Nuwellis · Revenue · Quarterly

$2.37M

Q3 2024-1.9%vs Q3 2023
Beat estimate in 4 of 14 quarters(29%)
ActualEstimate

Forward guidance

The company anticipates continued growth and market adoption of Aquadex ultrafiltration therapy, supported by clinical evidence and favorable reimbursement changes.

Tailwinds

  • CMS reimbursement increase expected to expand the outpatient marketplace.
  • New clinical study supports reduction in heart failure readmissions.
  • Momentum with new accounts opening due to increasing awareness of Aquadex efficacy.
  • Aquadex is becoming the standard of care for fluid removal.
  • Gross proceeds received through warrant exercises will support operations.

Headwinds

  • Year-over-year revenue decrease due to decreased consumables utilization.
  • Decrease in US console sales.
  • Company is still loss from operations.
  • Forward-looking statements are subject to risks and uncertainties.
  • Company's ability to execute on commercialization strategy is subject to risks.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

-5.5%

Avg return

Earnings day

-10.5%

Avg return

5 days after

-16.7%

Avg return

30 days after

28%

15 / 54 earnings

Positive

+51.9%

Q1 2024

Best reaction

-29.9%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.0%-5.0%
Q4 2025+2.4%-2.3%-16.3%
Q3 2025-3.4%-11.9%-18.0%
Q2 2025+0.4%+8.4%-24.0%
Q1 2025-3.1%-5.1%-68.7%
Q4 2024-4.0%-7.9%-25.4%
Q3 2024+6.6%-0.6%-28.2%
Q2 2024-14.3%-30.2%-46.4%
Q1 2024+51.9%+47.1%+29.4%
Q4 2023-20.7%-18.3%-36.7%
Q3 2023-10.0%-12.9%-14.3%
Q2 2023-5.1%-3.0%-22.2%
Q1 2023-29.9%-37.8%-34.6%
Q4 2022-5.1%-6.5%-41.2%
Q3 2022-19.6%-16.7%-50.0%
Q2 2022-6.5%-4.2%+23.9%
Q1 2022+1.0%+2.9%-7.4%
Q4 2021-1.2%-6.1%+2.0%
Q3 2021-17.0%-13.2%-33.3%
Q2 2021+9.6%+7.9%+3.0%
Q1 2021-14.6%-8.9%+6.6%
Q4 2020+5.7%-6.2%-21.3%
Q3 2020-7.8%-7.0%+14.1%
Q2 2020-16.0%-32.0%-68.0%
Q1 2020-9.6%-14.6%+2.4%
Q4 2019-28.8%-33.9%-29.0%
Q3 2019-15.0%-23.0%-16.0%
Q2 2019-1.2%+2.0%+0.4%
Q1 2019-13.3%-13.3%-24.9%
Q4 2018-12.6%-25.6%-69.8%
Q3 2018+2.8%+4.7%-21.7%
Q2 2018-26.4%-37.4%-23.9%
Q1 2018-17.1%-18.8%-23.3%
Q4 2017-15.5%-25.7%-21.0%
Q3 2017-12.8%-15.6%-47.3%
Q2 2017-4.0%-13.3%-6.7%
Q1 2017-9.5%-1.4%-9.5%
Q4 2016-5.3%-12.0%-58.0%
Q3 2016-5.0%-5.0%+190.0%
Q2 2016-14.9%-16.0%-17.0%
Q1 2016+1.5%
Q4 2015-15.9%
Q3 2015-1.2%
Q2 2015+0.7%
Q1 2015-3.5%
Q4 2014-0.2%
Q3 2014-17.5%
Q2 2014+23.9%
Q1 2014+3.2%
Q4 2013+2.1%
Q1 2013+6.2%
Q4 2012+2.6%
Q2 2012-7.6%
Q4 2011+0.0%
Q3 2011

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro